Ascendis Pharma submits candidate for US market approval

Transcon PTH has been granted the orphan drug designation by both the US and EU, and the drug is now ready for an FDA review.

Photo: Kevin Grønnemann / MedWatch

Following two successful phase III studies of drug candidate Transcon PTH against hypoparathyroidism, a disease that can cause muscle cramps or pains due to the body producing low levels of the parathyroid hormone, or PTH, and calcium, Ascendis Pharma now feels prepared to seek US approval.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs